# Use the evidence to set a clear goal *knee regeneration queen creek — What the Evidence Shows* > knee regeneration queen creek evidence on soreness, blood-based care and claims about new cartilage. This page tells you what knee studies can show. It also tells you what they can’t prove. ## Separate less soreness from more cartilage Your knee may feel better while an X-ray stays unchanged. A changed scan may not ease the ache. The two results aren’t the same. Decide which result matters to you. The amount of wear matters in a study. Your knee may differ from the knees tested. Look for a change you’d notice at home. Easier walking means more than a broad claim. Regenerative medicine from QC Kinetix includes PRP prepared from your blood and placed into your knee by its clinic team without surgery. Here, regenerative medicine names blood-based care and doesn’t promise new cartilage. ## Read the PRP study in plain terms PRP stands for platelet-rich plasma. The clinic makes PRP by spinning blood drawn from you. The RESTORE trial compared PRP with saline in 288 adults. Saline is plain salt water used as the comparison treatment. The comparison asked whether PRP did more than salt water. PRP didn’t give a better pain result at twelve months. Cartilage change wasn’t better either. Some people in other studies still said they felt better. The studies don’t agree on relief. They agree that new cartilage isn’t a sure result. Ask how your knee matches the people studied. Then ask how long people felt better. ## Ask what result the clinic expects Ask whether the goal is less soreness. Then ask whether anyone expects more cartilage on a scan. Don’t let those two answers get mixed. Feeling better doesn’t prove cartilage grew. Check what the study used for comparison. Salt water tests a different claim than physical therapy. Ask how many people felt a useful change. An average can hide those who didn’t improve. Also ask about swelling and other unwanted effects. Your choice includes possible help and possible harm. No study can promise your own result. Use the evidence to ask sharper questions. ## Sources 1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 5. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 6. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint. US Food and Drug Administration, Center for Biologics Evaluation and Research — [MACI (autologous cultured chondrocytes on porcine collagen membrane)](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane). *FDA*, 2024. 7. The SUMMIT randomized trial treated 144 patients (mean age 33.8, mean lesion 4.8 cm2) with at least one symptomatic focal cartilage defect (Outerbridge III/IV, >=3 cm2) of the femoral condyle or trochlea. Matrix-applied characterized autologous cultured chondrocytes (MACI) improved KOOS pain (37.0 to 82.5) and function significantly more than microfracture (pain 35.5 to 70.9) at 2 years, with histological and MRI assessment of the repair tissue. This is what a positive cartilage-repair trial looks like - in young patients with a discrete hole, not a worn joint. Saris D, et al. — [Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.](https://pubmed.ncbi.nlm.nih.gov/24714783/). *The American journal of sports medicine*, 2014. DOI: 10.1177/0363546514528093. ## Bring clear notes to your visit Bring your X-rays, current medicines and brief notes about soreness. Write down the daily task you most want to regain. Plan roughly twenty-five to thirty minutes from central Queen Creek. Call the Phoenix-area clinic team at (602) 837-PAIN. Book a free consultation: --- Plain help for a sore knee. Understand a sore knee, what may ease it and when to seek care nearby. Plain help with knee soreness, nearby care and treatment choices. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, who benefit when readers book with their clinic team. © 2026 Queen Creek Knee Atelier. General health education only; a webpage cannot diagnose your knee or replace urgent medical care.